Combined malonic and methylmalonic aciduria
Combined Malonic and Methylmalonic Aciduria (CMAMMA) is a rare metabolic disorder characterized by the accumulation of malonic acid and methylmalonic acid in the body. This condition is caused by mutations in the ACSF3 gene, which plays a crucial role in the metabolism of certain types of fats and proteins. Individuals with CMAMMA may experience a wide range of symptoms, including developmental delay, intellectual disability, muscle weakness, and failure to thrive. Early diagnosis and management are critical for improving the quality of life for affected individuals.
Causes
CMAMMA is caused by mutations in the ACSF3 gene. This gene is responsible for encoding a protein that is involved in the metabolism of certain lipids and amino acids. Mutations in the ACSF3 gene disrupt this metabolic pathway, leading to the accumulation of malonic acid and methylmalonic acid in the body.
Symptoms
The symptoms of CMAMMA can vary widely among affected individuals. Common symptoms include:
- Developmental delay
- Intellectual disability
- Muscle weakness
- Failure to thrive
- Feeding difficulties
- Seizures
- Metabolic acidosis
Diagnosis
Diagnosis of CMAMMA typically involves a combination of clinical evaluation, family history, and laboratory tests. Laboratory tests may include blood and urine tests to measure the levels of malonic acid and methylmalonic acid. Genetic testing can confirm a diagnosis by identifying mutations in the ACSF3 gene.
Treatment
There is no cure for CMAMMA, but treatment focuses on managing symptoms and preventing metabolic crises. Treatment strategies may include:
- Dietary restrictions to limit the intake of certain fats and proteins
- Supplementation with vitamins and minerals
- Medications to manage symptoms such as seizures
- Regular monitoring of acid levels in the blood and urine
Prognosis
The prognosis for individuals with CMAMMA varies depending on the severity of symptoms and the effectiveness of management strategies. Early diagnosis and intervention can improve the quality of life for affected individuals.
NIH genetic and rare disease info
Combined malonic and methylmalonic aciduria is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Combined malonic and methylmalonic aciduria
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian